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Dean J. Kereiakes, MD
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Current U.S. and European guidelines recommend coro-
nary artery bypass graft (CABG) over percutaneous coro-
nary intervention (PCI) for multivessel coronary artery
disease (CAD) and confer a class IIb (of uncertain beneﬁt)
recommendation to PCI for improvement in survival (1,2).
Prior studies suggest that the magnitude of clinical beneﬁt
attributable to revascularization with either PCI or CABG
is enhanced among patients in whom revascularization is
complete (CR) versus incomplete (IR) (3,4). Although these
studies demonstrate that IR is associated with hazard for
death, myocardial infarction (MI), or additional revascu-
larization, this conclusion is limited by observational,
retrospective study designs, lack of randomization (IR vs.
CR) and reliance on post-procedural classiﬁcation of
revascularization completeness by the treating physician. To
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elucidate the incidence and clinical consequence(s) associ-
ated with IR (vs. CR), Garcia et al. (5) provide the most
systematic, comprehensive meta-analysis to date. The inves-
tigators conclude that CR: 1) is more often achieved by
CABG than PCI; 2) is associated with meaningful reduc-
tions in mortality, MI, and repeat coronary revascularization;
and 3) provides differential beneﬁt (vs. IR) regardless of how
CR is deﬁned (e.g., anatomic vs. physiologic). In addition,
the magnitude of relative survival beneﬁt attributable to CR
(vs. IR) was similar following either CABG or PCI revas-
cularization, which suggests that the adequacy of revascu-
larization inﬂuences subsequent clinical course as much or
more than the method of revascularization does. Although
the scope and magnitude of this meta-analysis is helpful to
inform therapeutic triage for revascularization, multiple
caveats exist.
First, this work has the inherent limitations of any post
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Vascular, Boston Scientiﬁc, and Reva Medical.data garnered from observational studies with heterogeneous
methodologies, endpoints, and endpoint deﬁnitions. In all
but 1 included study, the decision to perform IR or CR was
not randomized. The prevalence of protocol-driven late
angiographic follow-up across constituent studies is not
provided nor is any uniform algorithm for prompting repeat
revascularization. Despite efforts to avoid counting staged
PCI procedures as repeat revascularizations, this possibility
persists and preferentially disadvantages the PCI strategy.
Similarly, medical therapy was neither optimized nor stan-
dardized across treatment groups stratiﬁed by revasculari-
zation status (CR vs. IR), and no protocol prescribed
minimum duration of dual antiplatelet therapy following
PCI is speciﬁed.
Second, although the association between CR and
survival beneﬁt appears sound, conclusions regarding
secondary endpoints of MI or repeat revascularization are
limited by power, heterogeneity of study deﬁnitions, and
lack of independent adjudication. These limitations are
evident in the investigators’ conclusion that “a reduction in
MI was observed among PCI-treated patients (PCI: risk
ratio [RR]: 0.80, 95% conﬁdence interval [CI]: 0.71 to 0.91;
p ¼ 0.001, I2 ¼ 0%) but not among CABG-treated patients
(CABG: RR: 0.69, 95% CI: 0.44 to 1.10; p ¼ 0.12;
I2 ¼ 62%).” Indeed, the point estimate for MI risk reduction
by CR (vs. IR) for CABG exceeds that observed for PCI.
MI deﬁnitions varied across studies and revascularization
strategy and only 18 of 35 studies reported this endpoint.
Thus, the possibility that CR provides similar MI reduction
beneﬁt for both PCI and CABG exists.
Third, although the beneﬁt provided by CR (vs. IR)
persists regardless of deﬁnition(s) used (anatomic vs.
nonanatomic) (see Online Table 1 of Garcia et al. [5]), this
observation would be strengthened by demonstrating
a quantitative relationship between IR and risk of subse-
quent adverse outcomes. A graded, standardized quantiﬁ-
cation of IR (the residual SYNTAX [Synergy Between PCI
With Taxus and Cardiac Surgery] score) has been correlated
with adverse clinical events including mortality following
PCI in patients with acute coronary syndromes (6), multi-
vessel stable ischemic heart disease (7) and left main CAD
(8). Although the residual SYNTAX score post-PCI
predicts risk when applied as either a binary (0 vs. >0) or
graded (tertile) function, its risk discriminatory ability
appears greatest when used quantitatively (6,7). Despite
colinearity of baseline (pre-PCI) and residual (post-PCI)
SYNTAX scores, residual SYNTAX score provides incre-
mental predictive accuracy for late adverse clinical outcomes.
In the absence of a large-scale randomized trial com-
paring CR with IR in patients with multivessel CAD, the
work of Garcia et al. (5) provides evidence that CR should
be the goal of revascularization and is associated with
optimal clinical outcomes. Further insights are gleaned by
viewing this work in context with a patient-level analysis
from the SYNTAX trial (9). SYNTAX prospectively
employed a pre-procedural angiographic lesion complexity
Figure 2
Adverse Clinical Events and Completeness of
Revascularization
Major adverse cardiac and cerebrovascular events (MACCE) through 3 years by PCI
or CABG stratiﬁed by complete (versus incomplete) revascularization (revasc) in
the SYNTAX trial. Modiﬁed with permission from Head et al. (9). Abbreviations as in
Figure 1.
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1433score and required pre-operative consensus between the
interventional cardiologist and surgeon (the Heart Team)
regarding the number of vessels 1.5 mm in diameter
with 50% stenosis that required revascularization. Subjects
were categorized as incompletely revascularized when the
number of diseased segments treated did not match the pre-
operative Heart Team’s decision. Among 1,800 subjects
with left main and/or 3-vessel CAD, who were randomly
assigned to revascularization by either CABG or PCI, IR
was more frequent following PCI (43.3%) than CABG
(36.8%). Both the incidence of IR and the relative advan-
tage of CABG (vs. PCI) for achieving CR were directly
proportional to the complexity of CAD as reﬂected by
SYNTAX score tertile (Fig. 1). Major adverse cardiovas-
cular and cerebrovascular events (MACCE), the primary
composite clinical endpoint of the SYNTAX trial, was
signiﬁcantly increased through 3 years following IR by PCI
but not CABG (Fig. 2) and was largely driven by repeat
revascularization among PCI-treated subjects. When only
subjects with 3-vessel (non–left main) CAD are analyzed,
IR is again more frequent following PCI (48.3% vs. 42.8%
for CABG; p ¼ 0.07), and MACCE through 5 years is
more adversely inﬂuenced by IR after PCI than following
CABG (Fig. 3). Thus, adverse clinical outcomes appear
disproportionately inﬂuenced by IR (vs. CR) following PCI.
Differences in the completeness of revascularization ach-
ieved by PCI and the relative “weight” of adverse events
associated with IR following PCI may be reﬂected in the
relative survival advantage attributed to CABG (vs. PCI) in
recent randomized trials (9,10) and observational studies of
patients undergoing multivessel revascularization (11). Al-
though concordant, these observations must be tempered by
rapid evolution in catheter-based technology and techniques
for PCI, as well as wide intercenter variability in expertiseFigure 1
Incomplete Revascularization by SYNTAX Score
and Treatment
Incidence of incomplete revascularization by PCI or CABG stratiﬁed by SYNTAX
score tertile. Modiﬁed with permission from Head et al. (9). CABG ¼ coronary
artery bypass graft; PCI ¼ percutaneous coronary intervention; SYNTAX ¼ Synergy
Between PCI With Taxus and Cardiac Surgery.and outcomes achieved by either PCI or CABG. Indeed,
durable safety and efﬁcacy of PCI revascularization is
inﬂuenced by “optimal” drug-eluting stent (DES) selection.
In this regard, target vessel revascularization, MI, and stent
thrombosis are reduced by everolimus-eluting (EES) DES
platforms (vs. non-EES DES) (12,13). Indeed, the superi-
ority of EES for reduction in MI, target lesion revasculari-
zation, and stent thrombosis when compared with the
paclitaxel-eluting DES platform employed in the SYNTAX
trial, has been demonstrated by a large-scale randomized trial,
pooled analysis of multiple trials, and large-scale meta-anal-
yses (13–15).
Furthermore, the relative beneﬁt of EES (versus paclitaxel-
eluting stents) for reduction in late adverse clinical out-
comes is roughly proportional to the complexity (number ofFigure 3
Adverse Clinical Events and Completeness of
Revascularization by Treatment
MACCE through 5 years by PCI or CABG and completeness of revascularization
among subjects with 3-vessel disease (non–left main) in the SYNTAX trial (data
provided by Keith Dawkins, MD; data on ﬁle at Boston Scientiﬁc Corporation, Inc.
[September 2012]).
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1434lesions/vessels) of CAD being treated (16). It has been
suggested that the results of the SYNTAX trial, which
favored CABG (vs. PCI), particularly in subjects with
intermediate SYNTAX scores (i.e., 23 to 32), complexity
may have been different if EES had been used instead of the
ﬁrst-generation paclitaxel-eluting stents (17). Finally, in
addition to ischemia guidance with fractional ﬂow reserve
(18) and optimal DES choice, long-term outcomes fol-
lowing PCI (including reduction in death or MI) may be
improved by routine use of procedural intravascular ultra-
sound (19). The impact of a comprehensive, multifaceted
approach to optimize PCI revascularization outcomes with
EES (vs. CABG) will be evident when results of the
EXCEL (Evaluation of XIENCE PRIME or XIENCE V
versus Coronary Artery Bypass Surgery for Effectiveness of
Left Main Revascularization) randomized trial become
available. In EXCEL, patients with unprotected left main
coronary disease and SYNTAX scores 32 are randomly
assigned to revascularization with either PCI using EES and
adjunctive fractional ﬂow reserve/intravascular ultrasound
optimization or CABG. The experience and expertise of
individual centers is as important as the technology and
technique for PCI or completeness of revascularization. In this
regard, wide intercenter variability in MACCE too was
observed among subjects treated with either PCI or CABG in
SYNTAX and was not related to center enrollment volume
(20). Indeed, intercenter variability in MACCE for a given
revascularization modality (PCI or CABG) exceeded any
observed differences between PCI and CABG for the trial as
a whole. Thus, triage for revascularization must always be
made in the context of local experience and expertise.
In summary, the meta-analysis of Garcia et al. (5) suggests
that CR should be the objective for either PCI or CABG and
that CR is more commonly achieved by CABG. Further-
more, as CR appears to confer a survival advantage, objective
assessment(s) of the completeness of revascularization should
be incorporated into procedural quality/performance metrics
as well as criteria for appropriate utilization. Although the
beneﬁt of CR was evident regardless of deﬁnition(s) used,
a standardized, consensus deﬁnition that incorporates both
anatomic and physiologic data would greatly enhance across-
trial analyses of aggregate data in the future (21).
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